Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of autoantibody signatures in meningioma patients using human proteome array

ABSTRACT: Our objective was to identify the potential autoantibody markers in meningiomas using high-density human proteome arrays (~17,000 full-length recombinant human proteins). This study revealed the dysregulation of 489 and 104 proteins in grades I and II of meningioma, respectively, along with the enrichment of signalling pathways which play a major role in the manifestation of the disease. This study revealed the dysregulation of 489 and 104 proteins in grades I and II of meningioma, respectively, along with the enrichment of signalling pathways which play a major role in the manifestation of the disease. Autoantibody targets like IGHG4, CRYM, EFCAB2, STAT6, HDAC7A and CCNB1 were dysregulated across both grades.

ORGANISM(S): Homo sapiens

PROVIDER: GSE83507 | GEO | 2016/06/21

SECONDARY ACCESSION(S): PRJNA326211

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

MiRNA profiling of meningioma of different grades and histological subtypes

Project description:Although meningiomas are one of the most frequent primary intracranial tumors, there are only a few studies dealing with gene regulation processes in meningiomas. MiRNAs are key regulators of gene expression and regulation and miRNA profiles offer themselves as biomarkers for cancer development and progression. To investigate the role of miRNAs during meningioma growth and progression, we compared expression of 1205 miRNAs in 55 meningioma samples of different tumor grades and histological subtypes. We were able to classify histological subtypes in WHO grade I meningiomas with up to 97% accuracy (meningothelial versus fibroblastic) and different WHO grades with up to 93% accuracy (WHO I versus WHO III). We found significant downregulation of miRNAs on chromosome 1p36 and within two large miRNA clusters on 14q32 in high grade meningiomas, two regions that are yet associated with meningioma progression. We also identified several miRNAs associated with epithelial to mesenchymal transition differentially expressed in meningothelial meningioma compared to fibroblastic meningioma. Combined, our data show that meningiomas of different WHO grades and histological subtypes show a specific miRNA expression profile. Some individual miRNAs can also serve as potential biomarkers for meningioma progression.

2014-12-31 | GSE50641 | GEO

Mining the meningioma lanscape to identify biomarkers using LFQ

Project description:The project involved use of surgically resected meningioma tumor tissue and non tumor controls for performing global proteomic analysis on individual patient samples. The data generated was analysed using WHO grades and other radiological parameters inorder to identify markers that can aid in better patient prognostication.

2020-08-27 | PXD014852 | Pride

Global proteomic profiles of meningioma tissues reveal proteogenomic subtypes

Project description:Fresh-frozen meningioma tissues of varying WHO grades were analyzed by shotgun DDA proteomics. The proteomic profiles were compared and reflected a set of new clinical subtypes derived from genomic, epigenomic and transcriptomic data which improved risk stratification.

2021-02-18 | MSV000086901 | MassIVE

Human primary meningioma vs. non-neoplastic adult meningeal tissue

Project description:Meningiomas are common brain tumors that are classified into three World Health Organization grades (Grade I: benign, Grade II: atypical and Grade III: malignant) and are molecularly ill-defined tumors. The purpose of this study was identify microRNA (miRNA) molecular signatures unique to the different grades of meningiomas correlating them to prognosis. We have used a miRNA expression microarray to show that meningiomas of all three grades fall into two main molecular groups designated “benign” and “malignant” meningiomas. While all typical meningiomas fall into the benign group and all anaplastic meningiomas fall into the malignant group, atypical meningiomas distribute into either one of these groups. We have identified a miRNA signature that distinguishes benign meningiomas from malignant meningiomas. We studied the gene expression profiles of 340 mammalian miRNAs in 37 primary meningioma tumors by means of DNA microarrays.

2011-01-02 | E-GEOD-19720 | biostudies-arrayexpress

Homo sapiens

Project description:MiRNA profiling of meningioma of different grades and histological subtypes

| PRJNA218145 | ENA

Genomic landscape of meningiomas: genotyping

Project description:Meningiomas are one of the most common adult brain tumors. For most patients, surgical excision is curative. However, up to 20% recur. Currently, the molecular determinants predicting recurrence and malignant transformation are lacking. We performed global genetic and genomic analysis of 85 meningioma samples of various grades. Copy number alterations were assessed by 100K SNP arrays and correlated with gene expression, proliferation indices, and clinical outcome. In addition to chromosome 22q loss, which was detected in the majority of clinical samples, chromosome 18q and 6q loss significantly predicted recurrence and was associated with anaplastic histology. Five "classes" of meningiomas were detected by gene expression analysis that correlated with copy number alterations, recurrence risk, and malignant histology. These classes more accurately predicted tumor recurrence than Ki-67 index, the gold standard for determining risk of recurrence, and highlight substantial expression heterogeneity between meningiomas. These data offer the most complete description of the genomic landscape of meningiomas and provide a set of tools that could be used to more accurately stratify meningioma patients into prognostic risk groups. Tumor biopsies from 53 female and 32 male subjects with sporadic meningioma were identified from the UCLA Neuro-oncology Program Tissue Bank through institutional review board approved protocols. 57 tumors were designated "benign" WHO I, 20 tumors were "atypical" WHO II, and 8 were "anaplastic" WHO III. Affymetrix SNP arrays were performed according to the manufacturer's instructions on DNA extracted from flash frozen meningioma tumors.

2011-10-11 | E-GEOD-16583 | biostudies-arrayexpress

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

Project description:Meningiomas are common brain tumours arising from meningeal tissue. Despite the majority of them displaying benign features, they can cause mild to severe morbidity. The current main therapeutic approach is complete tumour resection commonly with adjunct radiation therapy. However, tumour location can hamper complete resection and chemotherapies are ineffective. In this study we aim to elucidate dysregulated pathways in meningioma pathogenesis and identify novel molecular targets by deciphering the proteome and phosphoproteome of different grades of meningiomas. Tumour lysates were collected from grade I, II and III frozenmeningioma specimens and three normal healthy human meninges.

2019-01-02 | PXD007073 | Pride

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

Project description:Meningiomas are common brain tumours arising from meningeal tissue. Despite the majority of them displaying benign features, they can cause mild to severe morbidity. The current main therapeutic approach is complete tumour resection commonly with adjunct radiation therapy. However, tumour location can hamper complete resection and chemotherapies are ineffective. In this study we aim to elucidate dysregulated pathways in meningioma pathogenesis and identify novel molecular targets by deciphering the proteome and phosphoproteome of different grades of meningiomas. Tumour lysates were collected from grade I, II and III frozemeningioma specimens and three normal healthy human meninges.

2019-01-07 | PXD007044 | Pride

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

2019-01-02 | PXD007125 | Pride

Homo sapiens

Project description:Evaluation of autoantibody signatures in meningioma patients using human proteome array

| PRJNA326211 | ENA